Board of Directors
Developing a Range of SVP-Enabled Candidates for Rare and Serious Diseases
SEL-403 for Pancreatic Cancer and Mesothelioma
SEL-302 for Methylmalonic Acidemia (MMA)
Events & Presentations
Historical Price Lookup
Board of Directors
Targeted Immunotherapies
Refractory & Chronic Tophaceous Gout:
Targeted Immunotherapies
Gene Therapies:
 Enabling new applications with the potential to provide multiple doses and mitigate harmful immunogenicity
Targeted Immunotherapies
 Advancing new therapies to
About Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by mitigating unwanted immune responses.
January 23, 2019
Announces Pricing of Public Offering of Common Stock
January 22, 2019
Announces Proposed Public Offering of Common Stock
Our Synthetic Vaccine Particles (SVP™) technology platform enables precision in communicating with the immune system.
control the content of third-party websites, and this hyperlink does not constitute an endorsement by of this site's content. Selecta's privacy procedures do not apply to the owners of this third-party website.
CONTINUEAbout Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Phase 1 trial is ongoing for a combination therapy consisting of SVP-Rapamycin and LMB-100 (Selecta’s SEL-403 product candidate) for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. is based in Watertown, Massachusetts.About
Board of Directors
Developing a Range of SVP-Enabled Candidates for Rare and Serious Diseases
SEL-403 for Pancreatic Cancer and Mesothelioma
SEL-302 for Methylmalonic Acidemia (MMA)
Events & Presentations
Historical Price Lookup
Board of Directors
Synthetic Vaccine Particles (SVP™) are targeted to interact with immune cells and induce antigen-specific immune responses. are compatible with a wide range of antigens and immunomodulators. The broad applicability and manufacturing scalability that we have demonstrated with our technology platform continues to enable us to engage in collaborations with leading industry organizations.
For further information about and the company’s collaboration opportunities, please contact 
has in-licensed pegadricase, a pegylated recombinant uricase from 
from 3SBio. Selecta's lead product candidate combines pegadricase with SVP-Rapamycin for the treatment of chronic severe gout, which impacts an estimated 160,000 patients in the alone.
is collaborating with the Duke University Medical Center on the potential to utilize SVP-Rapamycin to reduce the immunogenicity of biologic treatments for Pompe disease, which impacts approximately one in 12,000-40,000 people in the United States.
Genethon is providing adeno-associated virus (AAV)-based gene therapies and animal models to enable the use of products to mitigate the formation of anti-drug antibodies and to enable repeat administration in gene therapy.
The International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy is teaming with on an SVP-enabled gene therapy candidate for the treatment of Ornithine Transcarbamylase Deficiency (OTC), an inborn error of metabolism affecting approximately one in 15,000-60,000 newborns in the United States.
has in-licensed Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear for the treatment of several diseases, including Methylmalonic Acidemia (MMA), an inborn error of metabolism affecting approximately one in 25,000-48,000 newborns in the United States.
is collaborating with the National Cancer Institute (NCI) on the development of a combination product candidate consisting of LMB-100 and SVP-Rapamycin, known as Selecta's SEL-403 product candidate, as a potential treatment for pancreatic cancer, mesothelioma and other cancers.
is teaming with the Venditti laboratory at the National Human Genome Research Institute (NHGRI) on an SVP-enabled gene therapy candidate for the treatment of Melthylmalonic Acidemia (MMA), a rare inborn error of metabolism.
In 2014, was awarded an $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the National Institutes of Health (NIH), to support research into the development of a next-generation vaccine for smoking cessation and relapse prevention.
The Skolkovo Foundation has committed up to $2.7 million in research funding to support Selecta’s development of an immunostimulatory therapeutic to treat human papilloma virus-associated cancers by stimulating the immune system.About
Board of Directors
Developing a Range of SVP-Enabled Candidates for Rare and Serious Diseases
SEL-403 for Pancreatic Cancer and Mesothelioma
SEL-302 for Methylmalonic Acidemia (MMA)
Events & Presentations
Historical Price Lookup
Board of Directors
Для того, чтобы увидеть эту страницу на русском языке, нажмите здесь
SELECTA(RUS) is a wholly owned subsidiary of Biosciences, Inc. and is located in Moscow, Russia. SELECTA(RUS) is building a pipeline of targeted immunotherapies and vaccines in the areas of oncology and infectious diseases based on Synthetic Vaccine Particles (SVP™). Our activities in Russia aim at expanding Selecta’s portfolio of immunotherapies. SELECTA(RUS)’s R&programs are developed in close coordination with Selecta’s leadership team in Boston, Massachusetts.
«СЕЛЕКТА (РУС)» 100% дочерняя компания расположенная в Московской области (Россия). «СЕЛЕКТА (РУС)» занимается созданием портфеля проектов в онкологии и лечении инфекционных заболеваний, состоящего из иммунотерапевтических препаратов и вакцин, основанных на технологии создания cинтетических вакцинных частиц (SVP™). Наша деятельность в России направлена на расширение портфеля иммунотерапевтических препаратов с учетом реальных потребностей российских пациентов. Исследовательская деятельность «СЕЛЕКТА (РУС)» ведется в тесной координации с Inc. в Бостоне.Carsten Brunn, Ph.D.
President and CEO
Prior to joining Biosciences, Inc., Dr. Brunn was the President of Pharmaceuticals for the Americas Region at Bayer and a member of the Global Pharmaceutical Executive Committee. Prior to being appointed to that role in 2017, he was the President of Bayer Pharmaceuticals in Japan, a role he held since 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Over the last 25 years, Dr. Brunn has held a number of senior leadership positions in Europe, Asia and the United States at leading companies such as Eli Lilly, Novartis, Basilea and Bausch and Lomb.
Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Sciences. In addition, he studied at the University of Washington under a research scholarship. He received his Ph.in Chemistry from the University of Hamburg, Germany and completed his executive education at London Business School.
Chief Operating Officer and Senior Vice President, Research and Development
Prior to joining Biosciences, Inc. in 2008, Dr. Johnston spent nine years at Alkermes, Inc., ascending to the role of Vice President of Operations with responsibility for process development, scale‑up, and clinical manufacturing of pulmonary and sustained-release injectable products, as well as leadership of Alkermes’ manufacturing facility in Chelsea, Massachusetts. He was also a project leader and a member of steering committees at Alkermes for numerous products through various stages of development from Phase 1 through registration.
Dr. Johnston was an original member of Advanced Inhalation Research Inc., or AIR, a private company formed in 1998 and acquired by Alkermes in 1999. Prior to joining AIR, he was a lecturer in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.Sc. in Chemical Engineering from Queen’s University in Ontario, Canada, and his and Ph.in Chemical Engineering from the Massachusetts Institute of Technology (MIT).
Prior to joining Biosciences, Inc. in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, Inc., where he served in several leadership positions over the course of five years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease.
Prior to Momenta, he served as Senior Director of Inflammation Research at Millennium Pharmaceuticals, Inc., from 1999 to 2006, where he provided the scientific leadership for four programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell and The New England Journal of Medicine. Dr. Kishimoto received his from New College of the University of South Florida and his Ph.in Immunology from Harvard University.
Chief Financial Officer and Head of Corporate Strategy
Dr. Leaman joined Biosciences, Inc. in October 2017. He previously served as Head of Corporate Development at InfaCare Pharmaceutical Corp., a specialty pharmaceutical company that was recently acquired by Mallinckrodt plc. Prior to this, Dr. Leaman was Chief Financial Officer of Medgenics, Inc., a publicly traded biotech company. He also previously held senior roles at Shire plc and Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies.
Dr. Leaman brings to extensive licensing, merger and acquisition experience and began his career serving a range of life sciences companies as an Associate Principal at McKinsey & Company. He received an from the Perelman School of Medicine at the University of Pennsylvania, an from the Wharton School at the University of Pennsylvania, a in psychology, philosophy and physiology from Oriel College, University of Oxford while completing a Rhodes Scholarship, and a in biology from Elizabethtown College.
Chief Commercial Officer
Before joining Biosciences, Inc. in October 2017, Mr. Smolinski served as the Vice President and Head of Sanofi/Genzyme’s North American Rheumatology Business Unit, where he led the development of the company's commercialization plans for the rheumatoid arthritis medicine KEVZARA®. Prior to this, he served as Group Vice President of Immunology & Inflammation, Global Strategic Unit at Sanofi.
Mr. Smolinski also previously held senior commercial roles at Roche-Genentech, Bristol-Myers Squibb, Johnson & Johnson and Savient Pharmaceuticals. He earned a in health care administration from Oregon State University.
Prior to joining Biosciences, Inc., Dr. Brunn was the President of Pharmaceuticals for the Americas Region at Bayer and a member of the Global Pharmaceutical Executive Committee. Prior to being appointed to that role in 2017, he was the President of Bayer Pharmaceuticals in Japan, a role he held since 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Over the last 25 years, Dr. Brunn has held a number of senior leadership positions in Europe, Asia and the United States at leading companies such as Eli Lilly, Novartis, Basilea and Bausch and Lomb.
Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Sciences. In addition, he studied at the University of Washington under a research scholarship. He received his Ph.in Chemistry from the University of Hamburg, Germany and completed his executive education at London Business School.
Chairman, Co-Founder and Professor, Harvard
Omid Farokhzad, is one of our co-founders and has served as a member of our board of directors since 2007. Dr. Farokhzad is a Professor at Harvard Medical School, or HMS, and a physician-scientist in the Department of Anesthesiology at Brigham and Women’s Hospital, or Dr. Farokhzad established and directs the Center for Nanomedicine at BWH.
Prior to joining the faculty, Dr. Farokhzad completed his postgraduate clinical and postdoctoral research trainings, respectively, at BWH/and In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal, and economic contributions to America as an immigrant. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and Biological Engineering. He is the recipient of the 2013 Dr. Farokhzad has been directly involved in the launch and development of four biotechnology companies and, on occasion, has assumed additional roles in support of management. Dr. Farokhzad currently serves on the Board of Directors of Tarveda Therapeutics and Placon Therapeutics. From 2006 to 2014, Dr. Farokhzad served on the Board of Directors of Therapeutics, Inc. He received his and from Boston University School of Medicine, and his from Dr. Farokhzad's extensive knowledge of our business and the nanomedicine field and his medical training contributed to our board of directors' conclusion that he should serve as a director of our company.
Timothy Barabe joined our board of directors in July 2016. Mr. Barabe also serves on the boards of ArQule, Inc., Veeva Systems Inc., and Vigilant Biosciences, Inc., a private company. Mr. Barabe retired in June 2013 from his position as Executive Vice President and Chief Financial Officer of Affymetrix, Inc.
Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. From 2004 to 2006, he served as Chief Financial Officer of Regent Medical Limited, a based, privately owned, surgical supply company. Mr. Barabe served with Novartis from 1982 through August 2004 in a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe received his degree from the University of Massachusetts (Amherst) and his degree from the University of Chicago. Mr. Barabe's experience as a senior financial executive of life sciences companies and knowledge of the pharmaceutical and biotech industries contributed to our board of directors' conclusion that he should serve as a director of our company.
Managing General Partner, Polaris Venture Partners
Amir Nashat, Ph.D., has served as a member of our board of directors since 2008. Dr. Nashat has been a Managing General Partner at Polaris Venture Partners, a venture capital firm, since 2009 and focuses on investments in the life sciences. He currently serves on the board of directors of Fate Therapeutics, Inc., aTyr Pharma, Inc., Syros Pharmaceuticals and several private companies. Dr. Nashat has also served as a director of Receptos, Inc., Therapeutics, Inc., as well as Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company) and other private companies.
Dr. Nashat completed his Ph.as a Hertz Fellow in Chemical Engineering at with a minor in biology. Dr. Nashat earned both his and in materials science and mechanical engineering at the University of California, Berkeley. Dr. Nashat's extensive experience as a venture capitalist and board member to numerous companies in the biotechnology industry contributed to our board of directors' conclusion that he should serve as a director of our company.
Founder and of NanoDimension
Aymeric Sallin, M.S., has served as a member of our board of directors since 2008. Mr. Sallin has served as the Chief Executive Officer of NanoDimension, a venture capital firm, since 2002 and is the founder of that firm. Since 2014, Mr. Sallin has served as a strategic advisory board member of the École Polytechnique Fédérale de Lausanne, or EPFL.
Since 2002, Mr. Sallin has worked to promote nanotechnology around the world, and has received the Fellow Award and 2012 Alumni award for his contribution to the field of nanotechnology. Mr. Sallin has worked to generate and close investments of hundreds of millions of dollars into several for NanoDimension's portfolio companies. He currently serves as a board member of View, Inc., Technology and Tarveda Therapeutics. Mr. Sallin is also a member of the Swiss Academy of Engineering Science. Mr. Sallin received his Masters in Physical Engineering from in Lausanne, Switzerland. Mr. Sallin's extensive knowledge of our business and the nanomedicine field contributed to our board of directors' conclusion that he should serve as a director of our company.
Professor at Harvard Medical School and Children’s Hospital Boston
Timothy Springer, Ph.D., has served as a member of our board of directors since June 2016 and as a scientific advisor to us since December 2008. Since 1989, Dr. Springer has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011.
Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he is a founder, investor and board member of Scholar Rock and Morphic Therapeutic. Dr. Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer received a from the University of California, Berkeley, and a Ph.from Harvard University. Dr. Springer's extensive knowledge of our business and the nanomedicine field contributed to our board of directors' conclusion that he should serve as a director of our company.
Patrick Zenner served as President and Chief Executive Officer of Hoffmann-La Roche Inc., North America - the prescription drug unit of the Roche Group, a leading research-based healthcare enterprise - from 1993 to 2001.
Prior to his retirement, Mr. Zenner spent 32 years at Roche, joining the company as a sales representative in 1969. Mr. Zenner currently serves as Chairman of the Board and a director of both ArQule, Inc. and West Pharmaceutical Services, Inc. Previously, Mr. Zenner served as a director for Par Pharmaceuticals. Mr. Zenner received his from Creighton University and his from Fairleigh Dickinson University. We believe Mr. Zenner's extensive experience and expertise in the pharmaceutical industry qualifies him to serve on our board of directors.
